N-(2-甲氧乙基)哌啶-4-甲酰胺 | 73415-61-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-(2-甲氧乙基)哌啶-4-甲酰胺
• 英文名称: N-(2-methoxyethyl)-4-piperidinocarboxamide
• 英文别名: 4-[N-(2-methoxyethyl)carbamoyl]piperidine；N-(2-methoxyethyl)piperidine-4-carboxamide
• CAS: 73415-61-9
• 化学式: C₉H₁₈N₂O₂
• mdl: MFCD06739723
• 分子量: 186.254
• InChiKey: ZVOAVYXOJQFPGO-UHFFFAOYSA-N

物化性质

• 沸点：
  364.4±42.0 °C(Predicted)
• 密度：
  1.023±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  N-(2-甲氧乙基)哌啶-4-甲酰胺 、 2-氯-4-氨基-6,7-二甲氧基喹唑啉 在 三乙胺 作用下， 以 正丁醇 为溶剂， 反应 24.0h， 生成 1-(4-amino-6,7-dimethoxy-quinazolin-2-yl)-piperidine-4-carboxylic acid 2-methoxy-ethylamide
  参考文献：
  名称：

  2,4-Diamino-6,7-dimethoxyquinazolines. 2. 2-(4-Carbamoylpiperidino) derivatives as .alpha.1-adrenoceptor antagonists and antihypertensive agents

  摘要：

  A series of 4-amino-2-(4-carbamoylpiperidino)-6,7-dimethoxyquinazolines (2) were synthesized and evaluated for alpha-adrenoceptor affinity and antihypertensive activity. These compounds displayed high binding affinity (Ki, 10(-9)-10(-10) M) and selectivity for alpha 1-adrenoceptors in vitro, and 12, 14, 21-26, and 29 showed similar potency to prazosin. Compounds 26 and 28 were also shown to be competitive antagonists of the postjunctional, vasoconstrictor action of norepinephrine with no significant activity at prejunctional alpha 2-sites. The high binding affinity for series 2 is rationalized in terms of enhanced basicity of the quinazoline nucleus (pKa's: 12, 7.38; 26, 7.53; prazosin, 6.8) and hydrophobic interactions of the carbamoyl substituents. Molecular mechanics calculations and computer-assisted superimposition suggest that the quinazoline 2-substituents in prazosin and 2 occupy the alpha 1-adrenoceptor site in different manners. Antihypertensive activity was evaluated after oral administration (5 mg/kg) to spontaneously hypertensive rats, and 11, 15, 21, 22, and 26 displayed sustained prazosin-like efficacy at the 6-h time point. The high alpha 1-adrenoceptor affinity demonstrated by series 2 in vitro suggests that these marked, and prolonged, falls in blood pressure result from selective blockade of the alpha 1-mediated vasoconstrictor effects of norepinephrine.

  DOI：

  10.1021/jm00389a007
• 作为产物：
  描述：

  4-氯羰酰四氢-吡啶羧酸苄酯 在 palladium on activated charcoal 氢气 作用下， 以 氯仿 为溶剂， 25.0~50.0 ℃ 、344.73 kPa 条件下， 生成 N-(2-甲氧乙基)哌啶-4-甲酰胺
  参考文献：
  名称：

  2,4-Diamino-6,7-dimethoxyquinazolines. 2. 2-(4-Carbamoylpiperidino) derivatives as .alpha.1-adrenoceptor antagonists and antihypertensive agents

  摘要：

  A series of 4-amino-2-(4-carbamoylpiperidino)-6,7-dimethoxyquinazolines (2) were synthesized and evaluated for alpha-adrenoceptor affinity and antihypertensive activity. These compounds displayed high binding affinity (Ki, 10(-9)-10(-10) M) and selectivity for alpha 1-adrenoceptors in vitro, and 12, 14, 21-26, and 29 showed similar potency to prazosin. Compounds 26 and 28 were also shown to be competitive antagonists of the postjunctional, vasoconstrictor action of norepinephrine with no significant activity at prejunctional alpha 2-sites. The high binding affinity for series 2 is rationalized in terms of enhanced basicity of the quinazoline nucleus (pKa's: 12, 7.38; 26, 7.53; prazosin, 6.8) and hydrophobic interactions of the carbamoyl substituents. Molecular mechanics calculations and computer-assisted superimposition suggest that the quinazoline 2-substituents in prazosin and 2 occupy the alpha 1-adrenoceptor site in different manners. Antihypertensive activity was evaluated after oral administration (5 mg/kg) to spontaneously hypertensive rats, and 11, 15, 21, 22, and 26 displayed sustained prazosin-like efficacy at the 6-h time point. The high alpha 1-adrenoceptor affinity demonstrated by series 2 in vitro suggests that these marked, and prolonged, falls in blood pressure result from selective blockade of the alpha 1-mediated vasoconstrictor effects of norepinephrine.

  DOI：

  10.1021/jm00389a007

文献信息

• [EN] MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS<br/>[FR] INHIBITEURS DE PROSTAGLANDINE E SYNTHASE-1 (MPGES1) MICROSOMALE
  申请人：NOVASAID AB

  公开号：WO2011023812A1

  公开（公告）日：2011-03-03

  A compound of formula (I): as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compound. The compound is useful for the treatment of disorder selected from inflammatory diseases, nociceptive pain, auto-immune disease, breathing disorders, fever, cancer, inflammation related anorexia, Alzheimer's disease and cardiovascular diseases.

  公式（I）的化合物，以及其药用盐，以及包括该化合物的药物组合物。该化合物用于治疗选择自炎性疾病、伤害性疼痛、自身免疫疾病、呼吸系统疾病、发热、癌症、与炎症相关的厌食症、阿尔茨海默病和心血管疾病的紊乱。
• [EN] LOW MOLECULAR WEIGHT 2,5-DISUBSTITUTED THIOPHENE DERIVATIVES AND USE THEREOF IN THERAPY<br/>[FR] DÉRIVÉS DE THIOPHÈNE 2,5-DISUBSTITUÉS DE FAIBLE POIDS MOLÉCULAIRE ET LEUR UTILISATION EN THÉRAPIE
  申请人：NOVASAID AB

  公开号：WO2009098282A1

  公开（公告）日：2009-08-13

  A compound of formula (I). The compound is useful for the treatment of disorders such as pain, fever, inflammation and cancer. A method for preparing the compound.

  一种化合物的化学式（I）。该化合物可用于治疗疼痛、发热、炎症和癌症等疾病。一种制备该化合物的方法。
• 4-Amino-2-piperidino-quinazolines
  申请人：Pfizer Inc.

  公开号：US04243666A1

  公开（公告）日：1981-01-06

  Regulators of the cardiovascular system and, in particular, in the treatment of hypertension having the formula ##STR1## wherein R is lower alkyl; X, is a 3- or 4-position substituent and is --(CH.sub.2).sub.n CONR.sup.1 R.sup.2, --O(CH.sub.2).sub.n CONR.sup.1 R.sup.2 or ##STR2## wherein n is 0, 1 or 2; R.sup.1 is hydrogen or lower alkyl, and R.sup.2 is lower alkyl; lower alkenyl, lower alkynyl, phenyl, substituted phenyl, C.sub.3 -C.sub.7 cycloalkyl; lower alkyl substituted by phenyl, substituted phenyl, C.sub.3 -C.sub.7 cycloalkyl, halogen, trifluoromethyl, hydroxy, lower alkoxy, lower alkoxycarbonyl, phenoxy, substituted phenoxy or --NR.sup.3 R.sup.4 wherein R.sup.3 and R.sup.4 each represent hydrogen, lower alkyl, lower alkanoyl or lower alkylsulfonyl; with the proviso that any O, N or halogen atom in R.sup.2 is separated by at least 2 carbon atoms from the nitrogen atom to which R.sup.2 is attached; or R.sup.1 and R.sup.2 taken together with the nitrogen atom to which they are attached form a morpholino group optionally substituted by one or two lower alkyl groups, or a 1,2,3,4-tetrahydroisoquinolyl group optionally substituted on the benzene ring portion by one or two lower alkoxy groups; the pharmaceutically acceptable bioprecursors therefor, and the pharmaceutically acceptable acid addition salts thereof.

  心血管系统的调节剂，尤其是治疗高血压的化合物的公式为##STR1##其中R是较低的烷基；X是3-或4-位取代基，为--(CH.sub.2).sub.n CONR.sup.1 R.sup.2，--O(CH.sub.2).sub.n CONR.sup.1 R.sup.2或##STR2##其中n为0、1或2；R.sup.1为氢或较低的烷基，而R.sup.2为较低的烷基；较低的烯基，较低的炔基，苯基，取代苯基，C.sub.3-C.sub.7环烷基；较低的烷基被苯基，取代苯基，C.sub.3-C.sub.7环烷基，卤素，三氟甲基，羟基，较低的烷氧基，较低的烷氧羰基，苯氧基，取代苯氧基或--NR.sup.3 R.sup.4取代的；其中R.sup.3和R.sup.4分别表示氢，较低的烷基，较低的烷酰基或较低的烷基磺酰基；但R.sup.2中的任何O、N或卤原子与R.sup.2连接的氮原子至少相隔2个碳原子；或R.sup.1和R.sup.2与它们连接的氮原子一起形成一个吗啡基，该吗啡基可以选择地被一个或两个较低的烷基取代，或者一个1,2,3,4-四氢异喹啉基，该基可以选择地在苯环部分被一个或两个较低的烷氧基取代；其药用上可接受的生物前体，以及其药用上可接受的酸加盐。
• 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER
  申请人：Schiemann Kai

  公开号：US20110237583A1

  公开（公告）日：2011-09-29

  The present invention relates to pyridopyrimidine derivatives according to formula (I) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.

  本发明涉及公式（I）的吡啶嘧啶衍生物作为自体税脂酶抑制剂，以及使用这些化合物治疗和/或预防由于溶血磷酸酸水平增加和/或自体税脂酶的激活引起、介导和/或传播的生理和/或病理生理状况，特别是不同癌症。
• Azaquinazoline Inhibitors of Atypical Protein Kinase C
  申请人：Cancer Research Technology Limited

  公开号：US20160102094A1

  公开（公告）日：2016-04-14

  The present application provides a compound of formula (1) or a salt thereof, wherein R 7 , R 8 , R 9 , G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.

  本申请提供了一个公式（1）的化合物或其盐，其中R7、R8、R9、G和X的定义如本文所述。本申请进一步描述了包含这些化合物的组合物。公式（I）的化合物及其盐具有aPKC抑制活性，并可用于治疗增殖性疾病。